NCT02662556View on ClinicalTrials.gov

A Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg in Patients With Post-Operative Pain

PHASE3CompletedINTERVENTIONAL

Enrollment

140

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

June 30, 2016

Study Completion Date

July 31, 2016

Conditions

Acute Moderate-to-severe Pain

Interventions

DRUG

sufentanil sublingual tablet 30 mcg

sufentanil sublingual tablet 30 mcg as needed for pain management, but no more frequently than every 60 minutes, for up to 12 hours.

Trial Locations (2)

77401

HD Research, Houston

Research Concepts, Houston

All Listed Sponsors

lead

Talphera, Inc

INDUSTRY

NCT02662556 - A Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg in Patients With Post-Operative Pain | Biotech Hunter | Biotech Hunter